Isentress (Raltegravir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 12, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV
Isentress HD is given once daily in two 600-mg film-coated tablets in combination with other antiretroviral agents in appropriate patients with HIV-1 infection.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2017 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news
FDA Clears Raltegravir (Isentress HD) for HIV
FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 31, 2017 Category: General Medicine Source Type: news
Merck Receives FDA Approval of Isentress HD (raltegravir), a New Once-Daily Option for the Combination Treatment of HIV-1 Infection in Appropriate Patients
KENILWORTH, N.J.-- May 30, 2017 (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Isentress HD, a new 1200 mg once-daily dose of the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 30, 2017 Category: Drugs & Pharmacology Source Type: news
Comparable Long-term Outcomes With HIV Regimens Containing Raltegravir, Efavirenz Comparable Long-term Outcomes With HIV Regimens Containing Raltegravir, Efavirenz
Rates of death or progression to AIDS at four years are low and similar with antiretroviral regimens containing raltegravir or efavirenz, according to a new observational study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Merck ’s Isentress receives CHMP positive opinion to treat HIV-1 infection
Merck ’s Isentress (raltegravir) 600mg film-coated tablets have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for the treatment of HIV-1 infection in adults and paedi… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
KENILWORTH, N.J.--(Healthcare Sales & Marketing Network)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted... Biopharmaceuticals, Regulatory Merck, ISENTRESS, raltegravir, HIV/AIDS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 19, 2017 Category: Pharmaceuticals Source Type: news
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS ® (raltegravir) 600 mg in the European Union
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of ISENTRESS® (raltegravir) 600
mg film-coated tablets, in combination with other anti-retroviral
medicinal products, for the treatment of HIV-1 infection in adults and
pediatric patients weighing at least 40 kg.Language:
EnglishContact: MerckMedia:Pam Eisele, 267-30...
Source: Merck.com - Product News - May 19, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress
Global Blood Therapeutics (GBT) began the Phase IIa trial (GBT440-007) of GBT440 in adolescents with sickle cell disease (SCD), and Merck reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat a … (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2016 Category: Pharmaceuticals Source Type: news
Merck reports positive Phase III ONCEMRK trial of Isentress to treat HIV-1 infection
US-based pharmaceutical company Merck has reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat adults with HIV-1 infection. (Source: Drug Development Technology)
Source: Drug Development Technology - July 24, 2016 Category: Pharmaceuticals Source Type: news
Once-Daily Raltegravir Matches Twice Daily Efficacy (CME/CE)
(MedPage Today) -- Trial shows new dosing strategy feasible (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 23, 2016 Category: Infectious Diseases Source Type: news
Data for Merck's Investigational Once-Daily Formulation of ISENTRESS ® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation < /p > < p > EMA Accepts File A...
Source: Merck.com - Research and Development News - July 22, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK HIV ISENTRESS MSD NYSE:MRK Source Type: news
raltegravir (Isentress)
Title: raltegravir (Isentress)Category: MedicationsCreated: 2/5/2010 12:00:00 AMLast Editorial Review: 6/24/2016 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - June 24, 2016 Category: Infectious Diseases Source Type: news
Raltegravir Noninferior as Second-Line ART in Low-Resource SettingsRaltegravir Noninferior as Second-Line ART in Low-Resource Settings
A raltegravir-based regimen is an "appropriate alternative" for second-line antiretroviral therapy in resource-limited settings, a new phase 3 study confirms. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2016 Category: Infectious Diseases Tags: Family Medicine/Primary Care News Source Type: news
Single shot of PrEP drugs is 'as effective as taking HIV pills twice a day'
Scientists at the University of North Carolina found a high-dose of the drug raltegravir injected once a month could offer the same protection against HIV infection as taking PrEP drugs orally twice a day. (Source: the Mail online | Health)
Source: the Mail online | Health - March 22, 2016 Category: Consumer Health News Source Type: news
